Trump to announce expansion of non-ACA-complaint 'association health plans'

The Trump administration appears close to announcing a new health insurance option for small businesses and self-employed individuals that would offer fewer benefits and cost less.

The “association health plans” would cover pre-existing conditions, but they would not include all “essential health benefits” required by the Affordable Care Act. President Donald Trump has long argued such plans, which could be sold across state lines, would control premiums while delivering similar care.

Critics, however, claim the move would be disastrous, arguing the removal of consumer protections created by the ACA could lead to a death spiral in the insurance market as younger, healthier individuals leave the pool.

“To the extent that these plans develop and serve as a parallel market, that could have a destabilizing effect,” said Karen Pollitz of the nonpartisan Kaiser Family Foundation, an expert on individual health insurance, to the AP. “People who think they can get by without those (comprehensive) benefits will look for cheaper premiums,” she added.

Tuesday’s expected announcement comes eight months after Trump signed an executive order

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.